Year in Review: Dr. P Seo ⭐️Low dose colchicine assoc w/ ⬇️ incidence of hip/knee replacement ➡️ 5522 pts w/ stable CAD: colchicine 0.5 mg vs PBO for median of 28.6 months ➡️ Hip/knee: 2.5% vs 3.5% ➡️HR 0.69 Similar finding in 2020 CANTOS trial using Ilaris #ACR23 @RheumNow https://t.co/PD26zoolDB

Calling #rheumtwitter program directors! #ACR23 Plenary 0726 details considerations for developing MSUS curriculum from Canadian experts. Details below. https://t.co/VmbxkYwlcr @rheumnow https://t.co/5nrpDk0Dsc

Thinking beyond immunosuppression for SLE Nephritis management: SGLT-2i GLP-1RA ERAs @RheumNow #ACR23 https://t.co/RdmKnm08YY

Love teaching about the PsA-AxSpa-IBD venn diagram of disease manifestations Interesting idea, using fecal calprotectin to trigger colonoscopy in pts w/PsA/axSpA ~40% w/pathologic finding, 4.4% dx w/IBD Jives w/my clinical experience @RheumNow #ACR23 Abstr0495 #ACRBest https://t.co/rIQpJnup9v

Year in Review: Dr. P Seo Novel RA therapy on the horizon: ⭐️Peresolimab ➡️ stimulates PD1 ➡️ Phase II, 98 pts ➡️ tx-resistant to other therapies including biologics ➡️ Wk 12: better DAS28, ACR20, not ACR 50/70 #ACR23 @RheumNow

A possible curative therapy of an autoimmune disease via selective depletion of a TRBV-defined group of T cells. This could be potentially applicable to other HLA-B*27-associated spondyloarthropathies. Year in review, Seo #ACR23 @RheumNow https://t.co/NxxkpJhweH. https://t.co/41Po5CHid3

YR in Review: Dr. Seo 🚩GLORIA Trial RA pts > 65yo: prednisolone 5 mg/d x 2 yrs vs PBO + std care ➡️decr dz activity (DAS ⬇️0.37) but 24% incr ADE 🚩Extension: ➡️Tapered off pred over 3m and.. ⭐️NO ADRENAL INSUFF But, small incr in dz activity (DAS ⬆️0.23) #ACR23 @RheumNow https://t.co/YQbS6C8ZT5

#ACR23 Memorable Quote as reminded to us by Dr. P Seo during Year in Review: "What you think of as a rare manifestation of a common disease is probably a common presentation of a disease you are not aware of (yet)!" - Prof Seza Zen, MD @RheumNow https://t.co/Xhwb1brLKG

Yet another (mostly) reassuring report about lymphoma and DMARDS The skin cancer signal in the CIRT trial was weird; would be worth looking into that in observational studies as well @NamrataRheum #ACR23 Abst0438 @RheumNow https://t.co/Beg8UUe2mn

It seems so simple. We should be able to use proteomics to better pick winners when it comes to b/tsDMARDs in RA. Why is it hard? I guess: - theory ≠ practice - too many other factors - it's too easy not to Yet I hope/believe, one day we'll do better. #ACR23 ABST0427 @RheumNow https://t.co/5VBVp3KOJN

If you're >65 years old & have new RA, you start a DMARD, right? At worst, sometime in the first year? US Medicare data 2008-17 n=33,373 only 30% have a DMARD on file (of which bDMARD <10%) >5% on PNL alone Do we hate old people with RA?😔 @JihaRheum #ACR23 ABST0433 @RheumNow https://t.co/1CUXAh3fi0

Revisiting question in #painful #knee #osteoarthritis Which #steroid to inject - esp with #triamcinolone #hexacetonide shortages which is superior to #acetonide. New extended release #fluticasome #propionate > #placebo ? Is how about vs IA steroids LB04 @RheumNow @ACRheum #ACR23 https://t.co/qJazwihSe0

Kudos @AlexisOgdie & co for their work in this area Given proliferation of database research for causal inference, super important to have validated criteria to identify diseases Many spaces (looking at you sarcoidosis) where this is almost entirely absent @RheumNow #ACR23 https://t.co/krkgWAhjMr

#obesity is a significant RF for #osteoarthritis Assoc'd with: 💠impairment of gut biota 💠microbial translocation Leads to innate immune activation #ACR23 @RheumNow @rheumarhyme https://t.co/iuEvBh3A1j

I underestimated how much joy not-bankrupting our healthcare system would bring me ADA & RTX biosimilars have been wonderful; excited for IL6's to join the party @RheumNow #ACR23 Abstr0445 https://t.co/HGwi37rZpd